WallStreetZenWallStreetZen

NASDAQ: EXAS
Exact Sciences Corp Stock Forecast, Predictions & Price Target

Analyst price target for EXAS

Based on 10 analysts offering 12 month price targets for Exact Sciences Corp.
Min Forecast
$50.00-25.53%
Avg Forecast
$65.20-2.89%
Max Forecast
$95.00+41.5%

Should I buy or sell EXAS stock?

Based on 11 analysts offering ratings for Exact Sciences Corp.
Buy
Strong Buy
2 analysts 18.18%
Buy
6 analysts 54.55%
Hold
3 analysts 27.27%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EXAS stock forecasts and price targets.

EXAS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
SVB Leerink
Bottom 2%
2
BuyMaintains$75.00+11.71%2023-01-12
Piper Sandler
Top 25%
76
HoldMaintains$50.00-25.53%2022-11-14
Raymond James
Bottom 2%
2
BuyMaintains$60.00-10.63%2022-11-08
BTIG
Top 19%
82
Strong BuyMaintains$65.00-3.19%2022-11-07
Craig-Hallum
Bottom 3%
3
HoldDowngradesN/AN/A2022-10-19
Credit Suisse
Top 7%
94
BuyInitiates Coverage On$55.00-18.08%2022-08-25
Craig-Hallum
Top 34%
67
BuyMaintains$60.00-10.63%2022-08-03
Cowen & Co.
Top 14%
87
BuyMaintains$67.00-0.21%2022-08-03
Baird
Top 27%
74
BuyMaintains$75.00+11.71%2022-08-03
Citigroup
Top 5%
96
HoldMaintains$50.00-25.53%2022-08-03

1 of 2

Forecast return on equity

Is EXAS forecast to generate an efficient return?
Company
-12.92%
Industry
-20.91%
Market
47.78%
EXAS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EXAS forecast to generate an efficient return on assets?
Company
-6.37%
Industry
12.04%
EXAS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EXAS earnings per share forecast

What is EXAS's earnings per share in the next 2 years based on estimates from 8 analysts?
Avg 1 year Forecast
-$3.30
Avg 2 year Forecast
-$2.26

EXAS revenue forecast

What is EXAS's revenue in the next 2 years based on estimates from 8 analysts?
Avg 1 year Forecast
$2.3B+14.19%
Avg 2 year Forecast
$2.6B+31.88%
EXAS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXAS revenue growth forecast

How is EXAS forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
14.19%
Industry
5.61%
Market
72.18%
EXAS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXAS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXAS vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
EXAS$67.14$65.20-2.89%Buy
CRL$246.91$301.00+21.91%Strong Buy
QGEN$49.31$55.00+11.54%Strong Buy
PHG$17.27N/AN/AHold
DGX$145.39$147.83+1.68%Hold

Exact Sciences Stock Forecast FAQ

Is Exact Sciences Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NASDAQ: EXAS) stock is to Buy EXAS stock.

Out of 11 analysts, 2 (18.18%) are recommending EXAS as a Strong Buy, 6 (54.55%) are recommending EXAS as a Buy, 3 (27.27%) are recommending EXAS as a Hold, 0 (0%) are recommending EXAS as a Sell, and 0 (0%) are recommending EXAS as a Strong Sell.

If you're new to stock investing, here's how to buy Exact Sciences stock.

What is EXAS's earnings growth forecast for 2023-2024?

(NASDAQ: EXAS) Exact Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 33.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 85.2%.

Exact Sciences's earnings in 2023 is -$716,372,000.On average, 8 Wall Street analysts forecast EXAS's earnings for 2023 to be -$586,357,329, with the lowest EXAS earnings forecast at -$756,934,006, and the highest EXAS earnings forecast at -$492,184,788.

In 2024, EXAS is forecast to generate -$401,565,928 in earnings, with the lowest earnings forecast at -$493,961,628 and the highest earnings forecast at -$291,401,824.

What is EXAS's revenue growth forecast for 2023-2024?

(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 14.19% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.

Exact Sciences's revenue in 2023 is $2,005,096,000.On average, 8 Wall Street analysts forecast EXAS's revenue for 2023 to be $406,822,355,066, with the lowest EXAS revenue forecast at $391,427,809,927, and the highest EXAS revenue forecast at $416,313,703,377.

In 2024, EXAS is forecast to generate $469,860,920,738 in revenue, with the lowest revenue forecast at $458,144,257,522 and the highest revenue forecast at $483,815,869,793.

What is EXAS's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: EXAS) forecast ROA is -6.37%, which is lower than the forecast US Diagnostics & Research industry average of 12.04%.

What is EXAS's Price Target?

According to 10 Wall Street analysts that have issued a 1 year EXAS price target, the average EXAS price target is $65.20, with the highest EXAS stock price forecast at $95.00 and the lowest EXAS stock price forecast at $50.00.

On average, Wall Street analysts predict that Exact Sciences's share price could fall to $65.20 by Jan 12, 2024. The average Exact Sciences stock price prediction forecasts a potential downside of 2.89% from the current EXAS share price of $67.14.

What is EXAS's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: EXAS) Exact Sciences's current Earnings Per Share (EPS) is -$4.11. On average, analysts forecast that EXAS's EPS will be -$3.30 for 2023, with the lowest EPS forecast at -$4.26, and the highest EPS forecast at -$2.77. In 2024, EXAS's EPS is forecast to hit -$2.26 (min: -$2.78, max: -$1.64).

What is EXAS's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: EXAS) forecast ROE is -12.92%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.